Biotest AG: Biotest reaches FY 2017 EBIT guidance
Biotest AG / Key word(s): Preliminary Results
Biotest reaches FY 2017 EBIT guidance
The former EBIT guidance, which included the continuing and discontinued US operations, was reduced on April 26, 2017 after the albumin recall from EUR 46 to EUR 48 million to EUR 16 to EUR 23 million for the 2017 financial year. This guidance, which included the earnings contribution of the US companies, was reached with EUR 18 million.
The EBIT in continuing operations amounted to EUR -9.3 million in the 2017 financial year after EUR 35.2 million in the previous year.
One-off expenses from inventory write-offs, penalties and other costs for the recall of various batches of human albumin as well as legal and consulting fees in connection with the takeover by Tiancheng (Germany) Pharmaceutical Holdings AG, Munich, Germany in the amount of EUR 37.7 million had a negative impact on the EBIT of continuing operations.
Biotest will publish final results for the Financial Year 2017 and the annual report on March 22nd, 2018. The Annual General Meeting of Biotest AG will take place on May 15th, 2018 in Frankfurt /.M.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Dr. Michael Ramroth
Chief Financial Officer
Tel. +40 6103 801 338
Fax: +49 6103 801 347
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|